key: cord-0957945-sxs93hxp
authors: Akelew, Yibeltal; Andualem, Henok; Ebrahim, Endris; Atnaf, Aytenew; Hailemichael, Wasihun
title: Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy
date: 2021-12-03
journal: Immun Inflamm Dis
DOI: 10.1002/iid3.573
sha: 9fff919873a6f288a9c7e61d6b172920e2107f97
doc_id: 957945
cord_uid: sxs93hxp

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), an emerging virus in late 2019 causing coronavirus disease 2019 (COVID‐19), has caused a catastrophic effect, resulting in an unprecedented global crisis. The immunopathology of COVID‐19 appears to be clearly associated with a dysregulated immune response leading to organ failure and death. Similarly, over two billion people worldwide are infected with helminth, with those living in low‐middle‐income countries disproportionately affected. Helminth infections have been shown to possess immunomodulatory effects in several conditions. Helminth co‐infection in COVID‐19 patients is one of the potential reasons for global attention to answer why COVID‐19 severity is still lower in helminth endemic countries. Recent studies have shown that helminth endemic countries showed fewer cases and deaths so far and helminth co‐infection might reduce the severity of COVID‐19. Moreover, lessons from other diseases with helminth co‐infection have been shown to substantially reduce vaccine efficacy that could also be implicated for COVID‐19. This immunomodulatory effect of helminth has intended and unintended consequences, both advantageous and disadvantageous which could decrease the severity of COVID‐19 and COVID‐19 vaccine efficacy respectively. Herewith, we discuss the overview of COVID‐19 immune response, immunomodulatory effects of helminth co‐infections in COVID‐19, lessons from other diseases, and perspectives on the efficacy of COVID‐19 vaccines.

been successfully developed much faster than the development of any other vaccines. SARS-CoV-2 is a singlestranded RNA virus (ssRNA) where the structural protein includes a Spike (S), Membrane (M), Envelope (E), and Nucleocapsid (N). 3 The spike (S) protein serves for the binding of SARS-CoV-2 to its receptor human angiotensinconverting enzyme 2 (ACE2) through its receptor-binding domain and further promotion of virus entry in to the cellmediated by human TM protease serine 2 (TMPRSS2) which has been found to co-express, co-localize and interact with ACE2. 4, 5 Following receptor binding, the virus can enter the cell cytoplasm via clathrin-mediated endocytosis. 6 1.1 | Immune responses to SARS-CoV-2

An effective immunologic response against SARS-CoV-2 requires both wings of immunity. Innate recognition of virus by pattern recognition receptor (PRR) like toll-like receptors (TLRs) and retinoic acid-inducible gene (RIG-1) results in the activation of the transcription factors, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), and interferon regulatory factor 3 (IRF3), resulting in translocation into the nucleus and inducing the expression of proinflammatory cytokines, chemokines, and type I interferon (IFN). 7 Besides upregulation of type 1 IFN gene and induction of aberrant inflammatory cytokines and chemokine's secretion like interleukin (IL)-6, IL-1β, IL-8, CCL2, CCL8, and CXCL9, exuberant activation of complement pathways results the overproduction of chemoattractants, C3a and C5a (anaphylatoxins) which will further induce recruitment of inflammatory cells leading cytokine storm. 8 Adaptive immune response against SARS-COV-2 has been revealed a positive association between antibody response and T-cell immune memory with disease severity. 9 Severe COVID-19 can also result CD4 + and CD8 + T cells exhaustion with increased cell surface expression of programmed cell death protein 1 (PD-1) and T-cells immunoglobulin and mucin domain 3 (Tim-3). 10 While the pathology of SARS-CoV-2 is not equivocally understood, at least we know it is mainly associated with hyperinflammatory responses, as characterized in the severe cases of patients. SARS-COV-2 dampens the antiviral IFN responses through unrestrained virus replication in several cells which results in the upregulation of activated macrophages, neutrophils, and other adaptive immune cells which lead to elevated pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. 11, 12 The reduced innate antiviral defenses coupled with hyperproduction of inflammatory mediators are the determinant factors of severe COVID-19. 13 Several studies have revealed that severe COVID-19 disease is characterized by increased levels of inflammatory cytokines, and chemokines as shown in Table 1 .

These cytokines and chemokines in turn attract other immune cells to migrate to the site of inflammation thereby cascading the intensification of inflammatory response as shown in Figure 1 . It has been reported that Th2/Th1 cytokine imbalance is related to higher risk of mortality. 29 Hence, the presence of excessive production of pro-inflammatory cytokines, referred to as "cytokine storm"; which leads to widespread tissue damage involving acute respiratory distress syndrome or multiorgan failure which is linked with mortality in COVID-19 patients. 10, 30 As a result, immunomodulatory therapeutic approaches targeting the pro-inflammatory cytokines have been applied to alleviate COVID-19 severity. 31, 32 Keep this in mind, herewith; we elucidate the interaction of helminth with other diseases, and insights to SARS-COV-2 and the potential implications of helminth co-infection in the context of COVID-19 vaccine efficacy.

Parasitic helminths are still a major health problem worldwide, affecting more than 2 billion people (approximately one-third of mankind) where most helminth infections are observed among the resource-limited countries. 33 According to the World Health Organization (WHO) report, sub-Saharan Africa accounts 85% of the neglected tropical disease burden resulting from helminth infections. 34 Helminth infections are known to induce immune regulatory responses in the host that can be helpful to control inflammation. 35 In paradox, helminth infections do have a significant public health burden, particularly in low and middle-income countries, 36-38 associated with high rates of morbidity, with chronic infection typically resulting in anemia and malnourishment and even severe manifestations like elephantiasis and blindness. 39, 40 Helminth-induced immunomodulation reduces the host immune response by permitting parasite survival and minimizes tissue damages. As a result, most peoples with helminths are unaware of their infection.

Innate immunity is the first line response and typically identifies pathogens based on germline-encoded receptors that detect the conserved components of pathogens.

Helminths and productions of excretory/secretory product are recognized by receptors of phagocytes and other cells types, which participate in an intricate cytokine network to generate innate Th2 responses which in turn drives the polarization of AAM, and the activation of eosinophils, basophils, innate lymphocyte T cells 2 (ILC2s), and mast cells. 41, 42 The fact that helminth parasites negatively regulate TLRs to a much larger degree suggests that the immune response to helminths could also influence subsequent activation of B and T lymphocytes. 43 Besides TLR signaling modulation, helminth-derived immunomodulatory molecules such as cytokine & innate defense homologs and growth factors, enzymes and inhibitors, lipids, and lipid-binding mediators have been largely revealed in modulation of the innate immune response. 44 

It is clear that adaptive immunity is initiated when an innate immune response fails to eliminate a pathogen. The infection with helminth modulates CD4 + T cell differentiation, induces the activity of regulatory T cell (Treg) responses, regulates immunoglobulin class switching, and induces a regulatory B cell (Breg) response, and thereby dampening the host immune responses. 44 These complex interactions result in the skewness of host immunity towards the type 2 immune response. 45 This is typically characterized by the induction of cytokines such as IL-4, IL-5, IL-9, IL-13, and IL-21, and usually the absence of IFN-γ and IL-17 production. 39 Besides, the Th2 responses support the initiation of Treg response that dampens the host Type 1 immune response pathway 45, 46 (Table 2) . Higher levels of IL-2R, IL-6, IL-10, and TNF-α and lower IFN-γ production by CD4 + and CD8 + T and NK cell 14 Prospective (n = 29) Higher levels of IL-2R and IL-6 15 Retrospective (n = 48) Elevated IL-6 16 Retrospective (n = 548) Elevated IL-6 and Decreased lymphocytes, CD8 + T-cell, eosinophils, and platelets, Increased neutrophil count and neutrophils-to-lymphocytes ratio 17 Chi et al Many helminth species secrete a plethora of immunomodulatory proteins that bind to cellular receptors and induce the production of IL-10 from cellular sources. These proteins may also block chemokine release, and Treg development, or inhibit B cell regulatory signaling and transendothelial migration. 44

Helminth infections are notable to modulate systemic pro-inflammatory cytokines and chemokines, which show a significant implication in a wide range of comorbidities. For example, a study done in India among type 2 diabetes mellitus patients shows that Strongyloides stercoralis alleviated the pro-inflammatory milieu while anthelmintic therapy partially restores the plasma pro-inflammatory cytokine and chemokine levels. 54 Helminth immunomodulatory effects have been also observed in many other conditions such as Mycobacterium tuberculosis infection, 55, 56 atopy, asthma, 57 and Autoimmune disease. 58 Besides this, helminth secretome has recently been shown as a novel therapeutic avenue for inflammatory disorder. 59 Helminth or its derived product treatment induces Treg and/or alternatively activated macrophages (AAMs) which could directly slow down allergen-specific Th2 responses through a cell contact-dependent mechanism, synthesis of common immunomodulatory mediators such as IL-10 and TGF-ß inhibiting IFN-γ secreting cell (Th1), and inhibition of binding allergen-specific IgE via helminth-specific, and nonspecific polyclonal IgE production called IgE blocking hypothesis. 60 The hypothesis that helminths infection modulates the immune response to viral infection is evident and corroborated by an experimental study by Rolot et al. The study uses the inoculation of eggs and adults of Schistosoma mansoni to murid herpesvirus 4 (MuHV-4) infected mice. They explored the helminths induced IL-4 dependent (possibly Th2 source) control of virus. 61 Similar study has also shown that the helminth-derived immunomodulator AvCystatin, derived from filarial nematode reduced respiratory syncytial virus (RSV) associated inflammations by inducing CD4 + T cells producing IL-10 cytokine. 62 In addition, helminths such as Heligmosomoides polygyrus can induce a protective antiviral response to respiratory syncytial virus. This is primarily mediated through the interaction between microbiota and upregulation of type-I IFN signaling. 63 On the other hand, a study by Osborne et al. 64 showed co-infection of helminth in viral infection resulted in diminished antiviral immunity, which is highly dependent on Ym1, a chitinase-like molecule that was associated with AAM without changes in the microbiota. However, the antiviral immunity was partly restored by the neutralization of Ym1. 64 Such scenarios could have a similar impact on immunity to COVID-19 aforementioned and which in turn affect the response to the COVID-19 vaccine.

After the emergence of SARS-COV-2, several reports on the severity of COVID-19 variations among different countries with the possible factors have been raised from researchers all over the world. The observation that the low number of severe cases and deaths due to COVID-19 in resource-limited nations has been a puzzle for scientists.

The situation was similar in settings where there is a high Bacillus Calmette-Guérin (BCG) vaccine coverage and helminth infections, which has attention. This was the concept of trained immunity that defines the innate immune response to induce memory more specifically BCG could result in protection against SARS-CoV-2 infection and might reduce the severity of COVID-19. [65] [66] [67] Moreover, based on the recent data reviewed, the high reactivity of BCG-derived antigen to its corresponding SARS-COV-2 substantially increased type II IFN production and its effect on CD4 + T-cells and nonspecific immune responses could harness cross-protection against severe COVID-19. 66 Despite, studies not explored and compared with lowmiddle-income countries and developed countries yet, a review by Yildirim et al. also indicated that the genetic variants of the SARS-CoV-2 entry human angiotensinconverting enzymes ACE2 receptor and related, IFNs, interleukins, TLRs gene, MHC, and ABO gene locus, are critical factors to determine severe COVID-19. 68, 69 Interestingly, based on global helminth endemic countries, the comparatively low impact of the COVID-19 disease in tropical and subtropical areas of the world coincides with areas of highly prevalent helminth infections. 68 Moreover, it is not well known why the severity of COVID-19 remains lower in most of the resource-limited nations. Hence, we have attempted to summarize a few studies with hypotheses raised from several researchers as follows.

Bradbury et al. 69 commentary first described and drew attention to the possible reduction of COVID-19 severity by helminth co-infection due to helminth immunomodulation in helminth-endemic regions. Helminth co-infection in SARS-COV-2 infected patients could derive a parasitespecific Th2 innate and adaptive immune response with CD4 + T cells, eosinophils, IL-4, IL-5, and IL-10 thereby reduce hyperinflammation in patients with severe COVID-19. 70 On the contrary, Hays et al. 71 put their alternative hypothesis stated that helminths may indeed have a mitigating effect based on a theoretical and empirical evidence of the negative impact of helminth infections suggests. Fonte et al. 72 indicated that helminth coinfection, in conjunction with other factors such as low testing system, age, and genetic background, SARS-CoV-2 variant, BCG vaccination, environmental conditions, and endemicity of other infections, could be the possible reasons for low lethality in sub-Saharan Africa.

Hillyer 73 has indicated to dedicate towards combating both SARS-COV-2 and helminth infections but with an ongoing understanding of their interaction and effects. Here also, other authors have highlighted, not to forget the negative effect of helminths in regions where undernutrition is a dominating concern where it might present a greater hazard in persons at risk for SARS-CoV-2 infection. 74 A recent review also suggested the negative and positive effects of helminth which looks complex and requires exploring the disadvantages and the possible immunomodulatory effects in COVID-19 together. 75 Following several hypotheses, a recent study conducted in Ethiopia on COVID-19 confirmed patients showed that parasite coinfected patients were associated with reduced COVID-19 severity which suggests that parasite-driven immunomodulatory response might mute hyperinflammation associated with severe COVID-19. 76 In this context, parasite endemicity could be the possible reason for answering why COVID-19 severity remains lower in those endemic countries. However, not all parasites including protozoa will have immunomodulatory properties. 77 Besides this, the diversity of helminth species co-infection resulting in human hosts is such not easily to make conclusions. 70 While certain helminth infections could reduce the severity of COVID-19, other helminths at different life cycles can also exacerbate immunopathology. The immune response in acute stage of schistosomiasis is mostly associated with a Th1 type immune response which is dramatically shifted to a Th2 type cytokine expression when the females start to lay eggs. 78 Research data analyzed from Uganda showed that an inverse correlation between helminth endemic countries and COVID-19 cases or deaths in the world. 79 In addition, the direct and indirect effect of helminth in reducing other respiratory viruses could be taken as a lesson, which could potentially reduce pulmonary inflammation induced by COVID-19. In this context, helminth co-infections showed reduced COVID-19 severity. However, there is an urgent need to explore immunological profiles and elucidate the effect of species-specific parasite immunomodulatory effects on the severity of the SARS-CoV-2 infection. To the best of the author's knowledge, no study investigated the implication of helminth infection on the immune response to COVID-19. Thus, here we tried to show insight based on previous lessons and existing data on the immune response of COVID-19 related to helminth infection.

Scientists worldwide have made tremendous efforts to produce vaccines that aimed to protect from COVID-19. Many vaccine strategies for SARS-CoV-2 have demonstrated efficacy in clinical trials, including mRNA encoding of the SARS-CoV-2 spike glycoprotein, recombinant spike protein, adenovirus vector expressing the surface glycoprotein, as well as delivery of whole inactivated virus as reviewed from. 80 As of October 27, 2021, there are 155 vaccine candidates, 485 vaccine trials ongoing, and 42 of these vaccines have entered phase III clinical trials with 23 approved vaccines 81 and of these about 12 (Table 3 ) have reported efficacy in the peerreviewed literature. Similarly, the vaccination database shows 6.92 billion doses have been administered globally and out of these, 48.9% of the world population has received at least one dose of a COVID-19 vaccine and only 3.1% of people in low-income countries have received at least one dose. 82 Unfortunately, comparing vaccines based on currently available data would be difficult in different study populations under different conditions. Ideally, most COVID-19 vaccines are designed to elicit strong immune responses, by neutralizing antibodies, against the trimeric SARS-CoV-2 spike protein. 83 Besides this, an effective COVID-19 vaccine should induce longlasting protective immunity with simultaneous involvement of antibody and T cell responses. 84 Despite several factors that could reduce the efficacy of COVID-19 vaccines, here the focus of our review highlights the effect of helminth on COVID-19 vaccine efficacy particularly in helminth endemic countries that need extensive research based on the following baseline data from other diseases.

Several studies have been shown helminth coinfection and anthelminthic therapy could reduce and enhance the efficacy of a vaccine against several pathogens respectively. Litomosoides sigmodontis nematode infected BALB/c mice model has been shown suppression of the humoral response to thymus-dependent vaccination, thereby the numbers of antigen-specific B cells, as well as Th2-associated IgG1 and TH1-associated IgG2 responses were suppressed. 85 Helminth infection impaired the immunogenicity of a Plasmodium falciparum DNA vaccine. 86 On contrary, in mice model to malaria transmission-blocking vaccine P. falciparum (pfs230D1-EPA/Alhydrogel®), Chronic helminth infection has induced a marked increase in systemic Th2 and regulatory cytokine levels in but could not able to alter vaccine specific-antibody level immune response. 87 Reduced antibody response to the live attenuated oral cholera vaccine CVD 103-HgR has been observed in children treated with Albendazole for ascariasis. 88 Moreover, reduced cellular and humoral responses have been observed in humans for tetanus toxoid with concurrent Wuchereria bancrofti infection. 89 In a trial done in the USA for the efficacy of pneumococcal vaccine, mice that have been vaccinated with either commercial conjugate or purified polysaccharide vaccines had impaired antibody responses if they were chronically infected with Taenia crassiceps. This translated to increased susceptibility to pneumococcal pneumonia and high mortality compared to helminthnegative vaccinated animals, which were fully protected from disease and death. Antibodies taken from Taeniainfected vaccinated mice were unable to effectively opsonize S. pneumoniae for killing by alveolar macrophages and did not protect against pneumococcal challenge when adoptively transferred into naïve animals. 90 A study done in Uganda has been shown that helminths are known to have implications in response to immunization of BCG, and on the incidence of infection and disease. Clinical trials done in Ethiopia to explore the effect of deworming on human T-cell response to mycobacterial antigen showed anthelminthic therapy improved mycobacterial antigen (PPD) specific cellular responses compared with the placebo group. 91 On the other hand, studies of clinical trials showed BCG vaccination had immunomodulatory properties that could protect against respiratory infections. It has been hypothesized that Bacillus Calmette-Guerin (BCG) vaccination might reduce the severity of COVID-19 by inducing trained immunity leads to epigenetically trained populations of monocytes and/or natural killer cells, which most likely reside in the bone marrow. 65 Helminths reduce Th1 and Th17-induced antiviral activity and vaccination efficacy. 75 Here, from findings of previous studies on the effect of helminth in reducing vaccine efficacy, several approved vaccines of COVID-19 could have various efficacies in different populations. Thus, considering studies that assess the response of vaccines in a variety of geographical and demographic areas may give worthful data and it will enhance the efforts of the world to end the pandemic.

Importantly, lessons from other respiratory viral infections have been also shown that helminth co-infection AKELEW ET AL. COVID-19 severity. Identifying immunological mechanisms and immunomodulatory components could bring new insights into the immunological and molecular mechanisms, which have a dual benefit to enable the current efforts for mitigating COVID-19 and enhancing the efficacy of current vaccines. The effect of helminth on vaccine efficacy in different conditions remains unclear and relatively little information is available. It is essential to balance the negative impact of helminth infections in resource-limited countries and potential immunomodulatory effects in COVID-19 patients. In general, we conclude, evidencebased data are urgently needed to identify the immunomodulatory effect of helminth-in COVID-19 patients that could have an impact on the clinical illness associated with SARS-CoV-2 infections in humans. Moreover, information gleaned from such studies on COVID-19 vaccine efficacy in helminth endemic countries will directly influence recommendations regarding whether deworming interventions for at risk communities in COVID-19 patients.

This study did not receive any specific grant from funding agencies.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

The molecular virology of coronaviruses

Cell entry mechanisms of SARS-CoV-2

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis

Innate and adaptive immune responses against coronavirus

Role of IFN and complements system: innate immunity in SARS-CoV-2

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

COVID-19: immunopathogenesis and Immunotherapeutics

Overview of immune response during SARS-CoV-2 infection: lessons from the past

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China

Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China

An inflammatory cytokine signature predicts COVID-19 severity and survival

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19

Characterization of the inflammatory response to severe COVID-19 illness

Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Th2/Th1 cytokine imbalance is associated with higher COVID-19 risk mortality

The COVID-19 cytokine storm; what we know so far

A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Effective treatment of severe COVID-19 patients with tocilizumab

Prevention and control of schistosomiasis and soil-transmitted helminthiasis World Health

Research Priorities for Helminth Infections: Technical Report of the TDR Disease Reference Group on Helminth Infections. World Health Organization

Human helminths and allergic disease: the hygiene hypothesis and beyond

Helminth infections: the great neglected tropical diseases

Control of soil-transmitted helminths in sub-Saharan Africa: diagnosis, drug efficacy concerns and challenges

Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis

Protective immune mechanisms in helminth infection

Helminth genomics: the implications for human health

Helminth infections: recognition and modulation of the immune response by innate immune cells

First responders: innate immunity to helminths

Activation and regulation of toll-like receptors (TLRs) by helminth parasites

Modulation of host immunity by helminths: the expanding repertoire of parasite effector molecules

Recent advances in type-2-cell-mediated immunity: insights from helminth infection

Helminth parasites and immune regulation

Chronic intestinal helminth infections are associated with immune hyporesponsiveness and induction of a regulatory network

Effect of Ascaris lumbricoides infection on T helper cell type 2 in rural Egyptian children

Hookworm excretory/ secretory products induce interleukin-4 (IL-4)+ IL-10+

CD4+ T cell responses and suppress pathology in a mouse model of colitis

Hookworm treatment induces a decrease of suppressive regulatory T cell associated with a Th2 inflammatory response

Nematode asparaginyl-tRNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis

Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis

Sm16, a major component of Schistosoma mansoni cercarial excretory/secretory products, prevents macrophage classical activation and delays antigen processing

Helminth infection modulates systemic pro-inflammatory cytokines and chemokines implicated in type 2 diabetes mellitus pathogenesis

Helminth mediated modulation of the systemic and mycobacterial antigen-stimulated cytokine profiles in extrapulmonary tuberculosis

Differential effects of asymptomatic Ascaris lumbricoides, Schistosoma mansoni or hook worm infection on the frequency and TGF-beta-producing capacity of regulatory T cells during active tuberculosis

Effects of helminth co-infections on atopy, asthma and cytokine production in children living in a poor urban area in Latin America

Helminth immunomodulation in autoimmune disease

Human helminth therapy to treat inflammatory disorders -where do we stand?

Helminth induced immunoregulation and novel therapeutic avenue of allergy

Helminth-induced IL-4 expands bystander memory CD8(+) T cells for early control of viral infection

The helminth-derived immunomodulator AvCystatin reduces virus enhanced inflammation by induction of regulatory IL-10+ T cells

Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota

Virushelminth coinfection reveals a microbiota-independent mechanism of immunomodulation

BCG-induced trained immunity: can it offer protection against COVID-19?

Bacille Calmette-Guerin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection -assumptions, knowns, unknowns and need for developing an accurate scientific evidence base

Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guerin vaccine: mechanisms, challenges and perspectives

Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19

The major genetic risk factor for severe COVID-19 is inherited from Neanderthals

The global helminth belt and Covid-19: the new eosinophilic link

Will helminth co-infection modulate COVID-19 severity in endemic regions?

Implications of helminth immunomodulation on COVID-19 co-infections

Helminth coinfection and COVID-19: an alternate hypothesis

COVID-19 lethality in Sub-Saharan Africa and helminth immune modulation

Parasites and parasitology in this SARS-CoV-2, COVID-19 world: an American Society of Parasitologists presidential address

COVID-19 and helminth infection: beyond the Th1/Th2 paradigm

SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: an epidemiological and immunological perspective

Effect of coinfection with parasites on severity of COVID-19. medRxiv

Not all parasites are protective

Current understanding of immunity against schistosomiasis: impact on vaccine and drug development

Parasites and their protection against COVID-19 -ecology or immunology. medRxiv

Landscape and selection of vaccine epitopes in SARS-CoV-2

COVID-19 Vaccine Tracker 2021

Coronavirus (COVID-19) Vaccinations

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms

Nematode-induced interference with vaccination efficacy targets follicular T helper cell induction and is preserved after termination of infection

Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice

Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. The

Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis

Chronic helminth infections impair pneumococcal vaccine responses

Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after Bacille Calmette-Guérin (BCG) vaccination

Helminth infections suppress the efficacy of vaccination against seasonal influenza

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

What went wrong with CureVac's mRNA vaccine?

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virusneutralising antibodies and mediates protection in rodents

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19> 14 d after the 2nd dose

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vectorbased COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Looking beyond COVID-19 vaccine phase 3 trials

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine

SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy

The authors declare that there are no conflict of interests.

Yibeltal Akelew wrote the manuscript draft. Henok Andualem, Endris Ebrahim, Aytenew Atnaf, and Wasihun Hailemichael contributed to the gathering of data, draft reviewing, and editing of the manuscript. All authors revised the manuscript and approved the final version of the manuscript before submission.

Data sharing not applicable to this article as no data sets were generated or analyzed during the current study.

http://orcid.org/0000-0002-8843-3913 Aytenew Atnaf https://orcid.org/0000-0002-9512-4369